Key Information
Source
JACC. Cardiovascular Imaging
Year
2019
summary/abstract
Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with a median survival from diagnosis, if untreated, ranging from 6 months for light chain amyloidosis to 3 to 5 years for transthyretin amyloidosis.
Early diagnosis and accurate typing of CA are necessary for optimal management of these patients. Emerging novel disease modifying therapies increase the urgency to diagnose CA at an early stage and identify patients who may benefit from these life-saving therapies.
The goal of this review is to provide a practical approach to echocardiography, cardiac magnetic resonance, and radionuclide imaging in patients with known or suspected CA.
Abstract Source
https://www.sciencedirect.com/science/article/abs/pii/S1936878X19307132?via%3Dihub
DOI
10.1016/j.jcmg.2019.07.015
Organisation
Brigham and Women's Hospital, USA